Category Specific RSS

PAR

Paradigm’s study could give options to those with this rare incurable disease

Clinical stage biopharmaceutical company Paradigm Biopharmaceuticals (ASX: PAR) has been given the green light to go ahead with a Phase…

4 years ago

Paradigm eyes FDA and TGA submission as patient data confirms major joint pain reduction

Clinical data trials being conducted by Paradigm Biopharmaceuticals (ASX: PAR) continue to deliver impressive patient outcomes for sufferers of chronic…

5 years ago

Paradigm clinical trial results identify breakthrough in fight against osteoarthritis

Osteoarthritis sufferers could soon receive effective pain relief and reduced onset from the degenerative disease after Paradigm Biopharmaceuticals (ASX: PAR)…

6 years ago